MRNAModerna, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $1.9B
- 40% YoY
- Operating margin
- -158.1%
- 30% YoY
- EBITDA
- −$2.9B
- 24% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$1.1B net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired25% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B | 40% |
| Operating income | $13.3B | $9.4B | −$4.2B | −$3.9B | −$3.1B | 22% |
| Net income | $12.2B | $8.4B | −$4.7B | −$3.6B | −$2.8B | 21% |
| Operating cash flow | $13.6B | $5.0B | −$3.1B | −$3.0B | −$1.9B | 38% |
| Capex | $284M | $400M | $707M | $1.1B | $192M | 82% |
| Stock-based comp | $142M | $226M | $305M | $429M | $483M | 13% |
| Buybacks | $857M | $3.3B | $1.2B | $0 | $2M |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $34M · 8
- Net
- −$34M
Pay vs performance
No pay-versus-performance disclosure yet.